EFG
NWBO

Ethos Financial Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Ethos Financial Group’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.33K Hold
39,070
– – ﹤0.01% 636
2026
Q1 		$8.07K Buy
39,070
+10,720
+38% +$2.21K ﹤0.01% 534
2025
Q4 		$6.49K Buy
28,350
+3,000
+12% +$686 ﹤0.01% 522
2025
Q3 		$6.09K Sell
25,350
-23,700
-48% -$5.69K ﹤0.01% 500
2025
Q2 		$12.6K Buy
49,050
+25,350
+107% +$6.51K ﹤0.01% 465
2025
Q1 		$6.51K Hold
23,700
– – ﹤0.01% 440
2024
Q4 		$6.51K Hold
23,700
– – ﹤0.01% 382
2024
Q3 		$8K Hold
23,700
– – ﹤0.01% 295
2024
Q2 		$10K Hold
23,700
– – ﹤0.01% 282
2024
Q1 		$12K Buy
+23,700
New +$12K ﹤0.01% 279
2023
Q2 		– Sell
-22,200
Closed -$13.9K – 168
2023
Q1 		$13.9K Buy
+22,200
New +$13.9K ﹤0.01% 187

Other funds holding NWBO

CFM
Compass Financial Management Tampa, Florida $829M AUM
KFA
Kelleher Financial Advisors New York $705M AUM 16.14% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.86B AUM 22.16% 1-Year Est. Return

Ethos Financial Group's NWBO Position: Q2 2026 in Review

Ethos Financial Group held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q2 2026 at 39,070 shares worth $6.33K. The position accounts for ﹤0.01% of the portfolio, ranked #636.

Ethos Financial Group first reported a position in NWBO in Q1 2023 and has held it in 11 quarters since. The position peaked at $13.9K in Q1 2023. 8 funds tracked by Wall St. Rank hold NWBO as of Q2 2026.

  • Ethos Financial Group held 39,070 shares of Northwest Biotherapeutics, Inc. Common stock worth $6.33K as of Q2 2026.
  • Ethos Financial Group left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q2 2026.
  • Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of Ethos Financial Group's portfolio in Q2 2026, its #636 holding.
  • Ethos Financial Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2023 and has held it in 11 quarters since.
  • Ethos Financial Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $13.9K in Q1 2023.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2026.

Based on Ethos Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.